Johnson & Johnson (NYSE:JNJ) Trading Down 0.5% – Here’s What Happened

Shares of Johnson & Johnson (NYSE:JNJ) dropped 0.5% during trading on Monday . The stock traded as low as $143.49 and last traded at $143.79. Approximately 1,497,384 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 7,181,067 shares. The stock had previously closed at $144.47.

Analysts Set New Price Targets

Several analysts recently weighed in on JNJ shares. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Morgan Stanley lifted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada increased their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Trading Up 0.4 %

The stock has a market cap of $351.15 billion, a price-to-earnings ratio of 21.11, a P/E/G ratio of 2.52 and a beta of 0.51. The business’s 50 day moving average is $154.46 and its 200 day moving average is $156.35. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.66 EPS. As a group, equities analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.40%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Institutional Trading of Johnson & Johnson

A number of large investors have recently made changes to their positions in the company. Independent Solutions Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Independent Solutions Wealth Management LLC now owns 21,068 shares of the company’s stock valued at $3,414,000 after acquiring an additional 80 shares during the period. Lord Abbett & CO. LLC acquired a new position in Johnson & Johnson in the third quarter valued at $69,859,000. DGS Capital Management LLC raised its holdings in shares of Johnson & Johnson by 17.5% in the third quarter. DGS Capital Management LLC now owns 5,404 shares of the company’s stock valued at $876,000 after buying an additional 804 shares during the last quarter. Copley Financial Group Inc. purchased a new position in shares of Johnson & Johnson during the third quarter worth about $676,000. Finally, Retirement Systems of Alabama increased its position in Johnson & Johnson by 4.0% in the 3rd quarter. Retirement Systems of Alabama now owns 1,243,090 shares of the company’s stock valued at $201,455,000 after acquiring an additional 48,250 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.